Cerebral Mitochondrial Microangiopathy Leads to Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalopathy

References

1. 1.↵
   2. Nishino I,
   3. Spinazzola A,
   4. Hirano M

   . Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689–92 doi:10.1126/science.283.5402.689 pmid:9924029

   Abstract/FREE Full Text
2. 2.↵
   2. Nishigaki Y,
   3. Martí R,
   4. Copeland WC, et al

   . Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 2003;111:1913–21 doi:10.1172/JCI17828 pmid:12813027

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Hirano M,
   3. Nishigaki Y,
   4. Martí R

   . Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist 2004;10:8–17 doi:10.1097/01.nrl.0000106919.06469.04 pmid:14720311

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Spinazzola A,
   3. Marti R,
   4. Nishino I, et al

   . Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002;277:4128–33 doi:10.1074/jbc.M111028200 pmid:11733540

   Abstract/FREE Full Text
5. 5.↵
   2. Martí R,
   3. Nishigaki Y,
   4. Hirano M

   . Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. Biochem Biophys Res Commun 2003;303:14–18 doi:10.1016/S0006-291X(03)00294-8 pmid:12646159

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Garone C,
   3. Tadesse S,
   4. Hirano M

   . Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011;134(Pt 11):3326–32 doi:10.1093/brain/awr245 pmid:21933806

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Giordano C,
   3. Sebastiani M,
   4. Plazzi G, et al

   . Mitochondrial neurogastrointestinal encephalomyopathy: evidence of mitochondrial DNA depletion in the small intestine. Gastroenterology 2006;130:893–901 doi:10.1053/j.gastro.2006.01.004 pmid:16530527

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Giordano C,
   3. Sebastiani M,
   4. De Giorgio R, et al

   . Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 2008;173:1120–28 doi:10.2353/ajpath.2008.080252 pmid:18787099

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Nishino I,
   3. Spinazzola A,
   4. Hirano M

   . MNGIE: from nuclear DNA to mitochondrial DNA. Neuromuscul Disord 2001;11:7–10 doi:10.1016/S0960-8966(00)00159-0 pmid:11166160

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Millar WS,
    3. Lignelli A,
    4. Hirano M

    . MRI of five patients with mitochondrial neurogastrointestinal encephalomyopathy. Am J Roentgenol 2004;182:1537–41 doi:10.2214/ajr.182.6.1821537 pmid:15150004

    CrossRefPubMed
11. 11.↵
    2. Schüpbach WM,
    3. Vadday KM,
    4. Schaller A, et al

    . Mitochondrial neurogastrointestinal encephalomyopathy in three siblings: clinical, genetic and neuroradiological features. J Neurol 2007;254:146–53 doi:10.1007/s00415-006-0255-3 pmid:17294068

    CrossRefPubMed
12. 12.↵
    2. Scarpelli M,
    3. Ricciardi GK,
    4. Beltramello A, et al

    . The role of brain MRI in mitochondrial neurogastrointestinal encephalomyopathy. Neuroradiol J 2013;26:520–30 doi:10.1177/197140091302600505 pmid:24199812

    CrossRefPubMed
13. 13.↵
    2. Rousset P,
    3. Elmaleh-Bergès M,
    4. Ogier de Baulny H, et al

    . Mitochondrial neurogastrointestinal encephalomyopathy [in French]. J Neuroradiol 2008;35:121–24 doi:10.1016/j.neurad.2007.07.003 pmid:17904638

    CrossRefPubMed
14. 14.↵
    2. Szigeti K,
    3. Sule N,
    4. Adesina AM, et al

    . Increased blood-brain barrier permeability with thymidine phosphorylase deficiency. Ann Neurol 2004;56:881–86 doi:10.1002/ana.20302 pmid:15562405

    CrossRefPubMed
15. 15.↵
    2. Mohamed S,
    3. Caporali L,
    4. De Giorgio R, et al

    . HPLC-UV analysis of thymidine and deoxyuridine in plasma of patients with thymidine phosphorylase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 2014;949–950:58–62 doi:10.1016/j.jchromb.2014.01.003 pmid:24463401

    CrossRefPubMed
16. 16.↵
    2. Malucelli E,
    3. Manners DN,
    4. Testa C, et al

    . Pitfalls and advantages of different strategies for the absolute quantification of N-acetyl aspartate, creatine and choline in white and grey matter by 1H-MRS. NMR Biomed 2009;22:1003–13 pmid:19504521

    PubMed
17. 17.↵
    2. Provencher SW

    . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260–64 doi:10.1002/nbm.698 pmid:11410943

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kreis R,
    3. Ernst T,
    4. Ross BD

    . Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:424–37 doi:10.1002/mrm.1910300405 pmid:8255190

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Kreis R,
    3. Slotboom J,
    4. Hofmann L, et al

    . Integrated data acquisition and processing to determine metabolite contents, relaxation times, and macromolecule baseline in single examinations of individual subjects. Magn Reson Med 2005;54:761–68 doi:10.1002/mrm.20673 pmid:16161114

    CrossRefPubMed
20. 20.↵
    2. Giordano C,
    3. d'Amati G

    . Evaluation of gastrointestinal mtDNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Methods Mol Biol 2011;755:223–32 doi:10.1007/978-1-61779-163-5_18 pmid:21761307

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Wardlaw JM,
    3. Smith C,
    4. Dichgans M

    . Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013;12:483–97 doi:10.1016/S1474-4422(13)70060-7 pmid:23602162

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Pantoni L

    . Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701 doi:10.1016/S1474-4422(10)70104-6 pmid:20610345

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Wardlaw JM

    . Blood-brain barrier and cerebral small vessel disease. J Neurol Sci 2010;299:66–71 doi:10.1016/j.jns.2010.08.042 pmid:20850797

    CrossRefPubMed
24. 24.↵
    2. Wolburg H,
    3. Lippoldt A

    . Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002;38:323–37 doi:10.1016/S1537-1891(02)00200-8 pmid:12529927

    CrossRefPubMedWeb of Science
25. 25.↵
    2. MacKay A,
    3. Laule C,
    4. Vavasour I, et al

    . Insights into brain microstructure from the T2 distribution. Magn Reson Imaging 2006;24:515–25 doi:10.1016/j.mri.2005.12.037 pmid:16677958

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Aung WY,
    3. Mar S,
    4. Benzinger TL

    . Diffusion tensor MRI as a biomarker in axonal and myelin damage. Imaging Med 2013;5:427–40 doi:10.2217/iim.13.49 pmid:24795779

    CrossRefPubMed
27. 27.↵
    2. Song SK,
    3. Yoshino J,
    4. Le TQ, et al

    . Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132–40 doi:10.1016/j.neuroimage.2005.01.028 pmid:15862213

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Xie M,
    3. Tobin JE,
    4. Budde MD, et al

    . Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features. J Neuropathol Exp Neurol 2010;69:704–16 doi:10.1097/NEN.0b013e3181e3de90 pmid:20535036

    CrossRefPubMed
29. 29.↵
    2. Sun SW,
    3. Liang HF,
    4. Le TQ, et al

    . Differential sensitivity of in vivo and ex vivo diffusion tensor imaging to evolving optic nerve injury in mice with retinal ischemia. Neuroimage 2006;32:1195–204 doi:10.1016/j.neuroimage.2006.04.212 pmid:16797189

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Klistorner A,
    3. Vootakuru N,
    4. Wang C, et al

    . Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter. PLoS One 2015;10:e0122114 doi:10.1371/journal.pone.0122114 pmid:25807541

    CrossRefPubMed
31. 31.↵
    2. Greenberg SM,
    3. Vernooij MW,
    4. Cordonnier C, et al

    ; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–74 doi:10.1016/S1474-4422(09)70013-4 pmid:19161908

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Fazekas F,
    3. Kleinert R,
    4. Roob G, et al

    . Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–42 pmid:10319975

    Abstract/FREE Full Text
33. 33.↵
    2. Inzitari D,
    3. Pracucci G,
    4. Poggesi A, et al

    ; LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three-year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009;339:b2477 doi:10.1136/bmj.b2477 pmid:19581317

    Abstract/FREE Full Text
34. 34.↵
    2. Filosto M,
    3. Scarpelli M,
    4. Tonin P, et al

    . Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol 2012;259:2699–706 doi:10.1007/s00415-012-6572-9 pmid:22711161

    CrossRefPubMed
35. 35.↵
    2. Halter JP,
    3. Michael W,
    4. Schüpbach M, et al

    . Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain 2015;138:2847–58 doi:10.1093/brain/awv226 pmid:26264513

    CrossRefPubMed
36. 36.↵
    2. De Giorgio R,
    3. Pironi L,
    4. Rinaldi R, et al

    . Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol 2016;80:448–55 doi:10.1002/ana.24724 pmid:27421916

    CrossRefPubMed